Ohio State researchers identify SET protein as potential glioblastoma treatment target
Researchers at Ohio State University's Comprehensive Cancer Center have identified the protein SET as a possible target to enhance existing glioblastoma treatments. In preclinical experiments, blocking SET prevented tumor development and increased cancer cell sensitivity to radiation by interfering with a biological pathway that helps tumors resist therapy. The findings remain preliminary and have not been tested in patients; researchers are now investigating whether safely targeting SET or related proteins can improve the effectiveness of standard radiation and chemotherapy for this lethal brain cancer.